Compare Travere Therapeutics Inc. Common Stock (TVTX) vs ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. (ZTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. trades at $19.97 (market cap $15.45B). The key difference: ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. is far larger — about 3.2× Travere Therapeutics Inc. Common Stock's market cap, and ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share. pays a 3.34% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals.
| TVTX | ZTO | |
|---|---|---|
Market Cap | $4.88B | $15.45B |
Volume | 1,668,577 | 1,928,522 |
Sector | Health | Industrials |
52-Week High | $67.52 | $25.88 |
52-Week Low | $26.79 | $18.59 |
Typical Hold Time | 0 Days | — |
Enterprise Value | $5.01B | $14.06B |
Dividend Yield | — | 3.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
ZTO Express trades at $20.67, up 1.08% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with $49.1B revenue, 19.03% net margin, and attractive valuation at P/E of 10.79. Recent Q2 2026 earnings beat expectations with 11% EPS growth, while analyst consensus remains strongly positive with 70% buy ratings.
ZTO presents compelling value with 50% upside to consensus target of $30.85, supported by pricing power and cost efficiencies. Risks include competitive pressures in China's delivery market and negative cash flow trends. The stock offers growth potential through market share gains and improved pricing environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About ZTO Express (Cayman) Inc. American Depositary Shares each representing one Class A ordinary share.
ZTO Express provides domestic and international express delivery services in China. Its network-partner model combines ZTO's sorting and trunk transportation with partners' pickup and last-mile delivery.
Read more on ZTO →
